Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treg/Th17-Related Cytokine Profile and Systemic Inflammatory Indices in Differentiated Thyroid Cancer: Relationship With Clinicopathological Features

NCT07907432 is registered in ClinicalTrials.gov with Marmara University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07907432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Treg/Th17-Related Cytokine Profile and Systemic Inflammatory Indices in Differentiated Thyroid Cancer: Relationship With Clinicopathological Features
Lead sponsor
Marmara University
Phase
Observational
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
October 31, 2027
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid cancer (dtc), nodular goiter, papillary thyroid carcinoma, thyroid cancer, thyroid nodule

Arms

As registered; 2 arms.

  • Differentiated thyroid carcinoma

    Participants undergoing elective thyroidectomy whose final histopathology shows differentiated thyroid carcinoma of papillary, follicular or oncocytic type.

  • Benign nodular goiter

    Participants undergoing elective thyroidectomy for a euthyroid thyroid nodule or nodular goiter whose final histopathology is benign.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Preoperative serum interleukin-17A concentration Baseline (1 day before surgery)

    Serum interleukin-17A concentration measured by ELISA in a blood sample obtained before surgery, compared between participants with differentiated thyroid carcinoma and participants with benign nodular goiter on final histopathology.

Lead sponsor's other trials

Marmara University, most recent start first.

Similar trials

Same condition (Goiter, Nodular) and phase, most recent start first.